Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO1020 Efficacy and Safety Study in Healthy Adults
NCT05636319Phase 3Active, not recruiting
- Sponsor
- Abogen Bioscience
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ABO1020 Group with Placebo Group (2 arms). Primary endpoints: Incidence of solicited adverse events, Incidence of unsolicited adverse events and 1 more. Started Nov 2022; status: active, not recruiting.
02
Drugs
ABO1020
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05636319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636319.